Waitlist

One list. Everything we offer. Everything coming up.

Leave your email and we'll let you know:

• When ojava restore opens for intake in your state for the compounds we already prescribe — sermorelin, NAD+, tesamorelin, PT-141.
• When any of the compounds currently on hold for FDA reclassification becomes legally compoundable through 503A pharmacies — including BPC-157, CJC-1295/Ipamorelin, TB-500, Thymosin Alpha-1, and AOD-9604.

One signup covers both. We won't email you for any other reason. No newsletters, no marketing campaigns, no third-party sharing.

Email only. Don't share medical or health details — we are not yet HIPAA-secured for clinical intake.

A note on timing.

Reclassification timelines are set by HHS and FDA, not by us. We can tell you the moment formal publication lands; we can't tell you when it will. If a provider tells you they know — or claims to be prescribing restricted compounds today on some technicality — they're either misinformed or willing to take risks with their license that we aren't.